Recommendation from the New Drugs Committee

First Page		Document Content
Chemotherapy regimens Bevacizumab FOLFOX Oxaliplatin Cetuximab Folinic acid Fluorouracil Vascular endothelial growth factor Colorectal cancer Medicine Chemistry Pharmacology		Recommendation from the New Drugs Committee Add to Reading List Source URL: www.scottishmedicines.org.uk Download Document from Source Website File Size: 78,04 KB Share Document on Facebook

	Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro DocID: 1v2t4 - View Document
	Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in DocID: 1t4Bh - View Document
	Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Minu K. Srivastava, Chr DocID: 1sS2d - View Document
	Theranostics 2016, Vol. 6, Issue 11 Ivyspring International Publisher Research Paper DocID: 1qwzN - View Document
	APPLI CATI O N N O T E Exploring gene promoters for experimentally-proven and putative transcription factor binding sites with TRANSFAC® Professional and the included Match™ tool TRANSFAC® Professional is a unique k DocID: 1q7G9 - View Document